We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+9.8%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.69B
AUM Growth
-$33.5M
Cap. Flow
+$39.4M
Cap. Flow %
2.34%
Top 10 Hldgs %
67.67%
Holding
67
New
9
Increased
19
Reduced
9
Closed
16

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$47.8M
2
ASND icon
Ascendis Pharma A/S
ASND
+$44.2M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$34.3M
4
SNY icon
Sanofi
SNY
+$30.8M
5
INBX
Inhibrx, Inc. Common Stock
INBX
+$19.4M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$29.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$18.1M
3
IRTC icon
iRhythm Holdings
IRTC
+$17.6M
4
UTHR icon
United Therapeutics
UTHR
+$14.7M
5
LLY icon
Eli Lilly
LLY
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
26
DexCom
DXCM
$27.6B
$15.9M 0.95%
140,678
-65,270
-32% -$7.17M
ISEE
27
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$13.7M 0.81%
638,398
-182,267
-22% -$3.89M
ALNY icon
28
Alnylam Pharmaceuticals
ALNY
$36.3B
$13.4M 0.8%
+56,448
New +$12M
TVTX icon
29
Travere Therapeutics
TVTX
$5.33B
$12.2M 0.72%
578,268
+183,590
+47% +$3.89M
YMAB
30
DELISTED
Y-mAbs Therapeutics
YMAB
$10.7M 0.64%
2,194,278
– –
IDYA icon
31
IDEAYA Biosciences
IDYA
$3.41B
$8.62M 0.51%
474,530
-180,226
-28% -$3.03M
IMGN
32
DELISTED
Immunogen Inc
IMGN
$8.36M 0.5%
1,686,154
+1,183,761
+236% +$6.42M
KURA icon
33
Kura Oncology
KURA
$922M
$7.37M 0.44%
+593,561
New +$8.63M
AGEN
34
Agenus
AGEN
$249M
$6.95M 0.41%
147,452
+23,263
+19% +$1.18M
RCUS icon
35
Arcus Biosciences
RCUS
$3.57B
$6.51M 0.39%
314,811
-66,534
-17% -$1.83M
GERN icon
36
CALL
Geron
GERN
$911M
$5.73M 0.34%
2,369,100
+1,297,000
+121% +$2.91M
FULC icon
37
Fulcrum Therapeutics
FULC
$248M
$4.6M 0.27%
631,411
-165,851
-21% -$1.08M
GRTX
38
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$4.59M 0.27%
3,083,712
– –
CYTK icon
39
CALL
Cytokinetics
CYTK
$11B
$4.58M 0.27%
+100,000
New +$4.3M
INZY
40
DELISTED
Inozyme Pharma
INZY
$3.84M 0.23%
3,655,308
– –
NXTC icon
41
NextCure
NXTC
$17.3M
$3.77M 0.22%
222,655
– –
NCNA
42
NuCana
NCNA
$5.37M
$3.7M 0.22%
1,120
– –
BOLT icon
43
Bolt Biotherapeutics
BOLT
$7.36M
$3.58M 0.21%
137,722
– –
GERN icon
44
Geron
GERN
$911M
$3.53M 0.21%
1,459,589
+270,381
+23% +$606K
AGEN
45
CALL
Agenus
AGEN
$249M
$3.04M 0.18%
+64,554
New +$3.28M
CTIC
46
CALL
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$2.46M 0.15%
+410,000
New +$2.24M
PDSB icon
47
PDS Biotechnology
PDSB
$38.1M
$1.88M 0.11%
142,635
– –
OBSV
48
DELISTED
ObsEva SA Ordinary Shares
OBSV
$689K 0.04%
4,749,623
– –
SYBX
49
DELISTED
Synlogic
SYBX
$437K 0.03%
38,331
– –
FUSN
50
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$369K 0.02%
117,099
– –
1
2
3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2022 Portfolio in Review

As of Q4 2022, Sofinnova Investments held 67 positions worth $1.69B, down 1.9% from $1.72B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Sofinnova Investments's Q4 2022 filing shows 9 new, 19 increased, 9 reduced and 16 closed positions. Its largest new stake was Vertex Pharmaceuticals: 156,989 shares worth $45.3M. The largest sale was Gilead Sciences, an estimated $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 91% a quarter earlier.

  • Sofinnova Investments's largest Q4 2022 buy was Vertex Pharmaceuticals: 156,989 shares worth $45.3M.
  • Sofinnova Investments added most to Ascendis Pharma A/S in Q4 2022, an estimated $44.2M increase.
  • Sofinnova Investments's biggest Q4 2022 reduction was United Therapeutics, cutting an estimated $14.7M.
  • Sofinnova Investments fully exited Gilead Sciences in Q4 2022, selling an estimated $29.8M.
  • Sofinnova Investments's ten largest holdings make up 68% of its $1.69B portfolio in Q4 2022.
  • Sofinnova Investments opened 9 new positions and closed 16 in Q4 2022.
  • Sofinnova Investments's portfolio value fell 1.9% quarter-over-quarter to $1.69B.

Based on Sofinnova Investments's 13F filing for Q4 2022, filed 14 Feb 2023.